Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Pauline Baumlin, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John F Seymour, Jonathan C Strefford, Georgina Meneses-Lorente, Nicolas Frey, Gunter Fingerle-Rowson
BLOOD | AMER SOC HEMATOLOGY | Published : 2017
Jamois: Roche: Employment, Other: GALLIUM was sponsored by F. Hoffmann-La Roche Ltd.. Gibiansky: Roche: Consultancy. Gibiansky: Roche: Consultancy. Buchheit: Roche: Employment. Baumlin: Roche: Employment. Sahin: Roche: Employment, Equity Ownership. Cartron: Sanofi, BMS, Jansen, celgene, Roche, Gilead: Equity Ownership; Celgene: Consultancy, Employment; Roche: Consultancy, Equity Ownership, Honoraria, Research Funding. Marcus: Roche: Consultancy, Honoraria, Other: Travel support, Speakers Bureau; Celgene: Other: Support for meeting attendance. Strefford: Roche: Research Funding. Meneses-Lorente: Roche Products Ltd: Employment. Frey: Roche: Employment. Fingerle-Rowson: F. Hoffmann-La Roche Ltd: Employment, Equity Ownership.